Results 171 to 180 of about 641,334 (295)

Can immersive virtual reality assess hypothermia resuscitation decision-making? A cross-sectional study in a civil-military disaster management context. [PDF]

BMJ Open
Lopez Lopez CA, Greif R, Semeraro F, Ocampo Cervantes AB, Pons Claramonte M, Nieto Caballero S, Pardo Ríos M, Guillen Martinez DM, Sánchez Gómez M, Georgiev MP, Ivanov ML, Lopez Ferrandiz L.   +11 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

An integrated multi-criteria decision-making model for long-term planning of UAVs in disaster management. [PDF]

PLoS One
Bakir ME, Kasimoglu F.
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Disaster management in India: are we fully equipped? [PDF]

J Soc Econ Dev, 2022
Deshpande RS.
europepmc   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Inclusiveness of disaster management for persons with disabilities in Türkiye from stakeholders' perspective. [PDF]

Sci Rep
Demiröz Yıldırım S.
europepmc   +1 more source

Decreasing corruption in the field of disaster management. [PDF]

Crime Law Soc Change, 2023
Ha KM.
europepmc   +1 more source

Essential work, invisible workers: The role of digital curation in COVID‐19 Open Science

Journal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 703-717, April 2025.
Abstract In this paper, we examine the role digital curation practices and practitioners played in facilitating open science (OS) initiatives amid the COVID‐19 pandemic. In Summer 2023, we conducted a content analysis of available information regarding 50 OS initiatives that emerged—or substantially shifted their focus—between 2020 and 2022 to address ...
Irene V. Pasquetto, Amina A. Abdu, Natascha Chtena   +2 more
wiley   +1 more source

Disaster Management, Disaster Governance, and Disaster Citizenship

Economy and Society, 2014
openaire   +1 more source